A*STAR teams with Cytos to combat HFMD
Singapore's Agency for Science, Technology and Research (A*STAR) has signed a deal with Swiss company Cytos Biotechnology to develop fully-human monoclonal antibodies for the treatment of Enterovirus 71 (EV71), one of the two most common viruses responsible for hand, foot and mouth disease.
Under the two-year agreement, A*STAR's Singapore Immunology Network will provide the immunological expertise, while Cytos will share its technology for the isolation of the antibodies that are highly specific to EV71.
Martin Bachmann, chief scientific officer of Cytos, said: "by means of this collaboration with SIgN we can apply our proprietary technology for human monoclonal antibodies also in the field of endemic diseases, an important area with urgent medical needs."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze